A statement released earlier today by Zacks Investment Research about Nevro Corp (NASDAQ:NVRO) bumps the target price to $110.00
- Updated: October 9, 2016
Stating a potential upside of 0.12%, Zacks Investment Research upped the price target of Nevro Corp (NASDAQ:NVRO) to $110.00
On Wednesday September 21, 2016, B. Riley released a statement on Nevro Corp (NASDAQ:NVRO) upped the target price from $0.00 to $114.00 that suggested an upside of 0.19%.
Having a price of $98.14, Nevro Corp (NASDAQ:NVRO) traded -2.01% lower on the day. With the last close up 19.84% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Nevro Corp has recorded a 50-day average of $97.65 and a two hundred day average of $78.56. Volume of trade was up over the average, with 572,059 shares of NVRO changing hands over the typical 488,108
With a total market value of $0, Nevro Corp has with a one year low of $36.51 and a one year high of $106.93 .
A total of 6 analysts have released a research note on Nevro Corp. One analyst rating the company a strong buy, five analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $80.67.
More About Nevro Corp (NASDAQ:NVRO)
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company's Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company's Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.